Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group

Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOOR-FSR enrolled on three Childrens Oncology Group phase 2 single arm trials. Benchmark endpoints assessed in this patient population were event-free survival (EFS) and overall survival (OS). In addition, we evaluated the impact of demographics and baseline clinical factors on outcome. Results: Ninety-nine patients met criteria for inclusion in this analysis. Median EFS and OS were 4.8 (95% CI: 3.5, 6.3) and 26.2 (23.3, 56.8) months respectively. Twelve-month EFS was 22% (15-31%) and ranged from 14% to 29% across the 3 trials, a difference that did not achieve statistical significance. The risk of EFS event was higher for those whose first recurrence occurred within two years of diagnosis (p=0.009). Other demographic and clinical factors did not statistically impact risk of event though estimated EFS for males was lower than for females. Conclusion: Despite almost doubling the number of patients in this historical control cohort, wide variance in outcomes led to confidence intervals unchanged from previously published work. Until the most significant factors contributing to variability of outcomes in this patient population are quantified, single arm trials of new approaches will only be able to identify large effect sizes. Smaller effect sizes will require randomization.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.26368045
Primary Topic
Sarcoma Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group

Steven G. DuBois, Alexander J. Chou, Richard Greg Gorlick, Natalie J. DelRocco et al.
medRxiv
Sarcoma Diagnosis and Treatment
preprint

Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group

Steven G. DuBois, Alexander J. Chou, Richard Greg Gorlick, Natalie J. DelRocco, Joanne Lagmay, Brenda J. Weigel, Elizabeth Fox, Katherine A. Janeway, Pooja Hingorani, Mark Krailo, Allen B. Buxton, Ryan Roberts, Damon Reed
preprint en

Abstract

Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOOR-FSR enrolled on three Childrens Oncology Group phase 2 single arm trials. Benchmark endpoints assessed in this patient population were event-free survival (EFS) and overall survival (OS). In addition, we evaluated the impact of demographics and baseline clinical factors on outcome. Results: Ninety-nine patients met criteria for inclusion in this analysis. Median EFS and OS were 4.8 (95% CI: 3.5, 6.3) and 26.2 (23.3, 56.8) months respectively. Twelve-month EFS was 22% (15-31%) and ranged from 14% to 29% across the 3 trials, a difference that did not achieve statistical significance. The risk of EFS event was higher for those whose first recurrence occurred within two years of diagnosis (p=0.009). Other demographic and clinical factors did not statistically impact risk of event though estimated EFS for males was lower than for females. Conclusion: Despite almost doubling the number of patients in this historical control cohort, wide variance in outcomes led to confidence intervals unchanged from previously published work. Until the most significant factors contributing to variability of outcomes in this patient population are quantified, single arm trials of new approaches will only be able to identify large effect sizes. Smaller effect sizes will require randomization.

medRxiv
University of Southern California (US), St. Jude Children's Research Hospital (US), Nationwide Children's Hospital (US), Memorial Sloan Kettering Cancer Center (US), UF Health Shands Hospital (US), The University of Texas MD Anderson Cancer Center (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), Weill Cornell Medicine (US)
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon